Abstract: A multiple-combination connector includes a housing which is formed by a lower housing and a matching upper housing. The lower housing has at least one opening. At least one socket is attached to the opening. A plurality of individual plugs which can be independently inserted into the socket. The connector can bring about a flexible combination of different types and different numbers of plugs/sockets and meet different application requirements. Since the design is that of a single plug, it is possible to assemble and disassemble the cables one by one, thereby facilitating assembly. The connector can prevent incorrect insertion and withstand disassembly and assembly. The problem of powder spraying is easily solved. The EMC functions, Ingress Protection (waterproof and dustproof) functions and protective earthing functions are implemented. The accumulation of rain, snow, ice and dust is effectively prevented, and small size and easy installation are achieved.

Abstract: Monoclonal antibodies against human Mac-1 are provided. These antibodies can bind to different states of Mac-1 so as to alter the biofunctions of Mac-1. These antibodies can modulate Th1/Th2 cytokine secretions by TLR-activated immune cells and can be used for the treatments of diseases related to acute and chronic inflammatory disorders, such as infectious diseases, and cancers.

Abstract: The present invention refers to oligonucleotides comprising 10 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with mRNA of angiotensin-converting enzyme 2 (ACE2) of SEQ ID NO.1 and/or with pre-mRNA of ACE2 of SEQ ID NO.2 resulting in a reduction of the level of ACE2, ACE2 mRNA, ACE2 pre-mRNA or a combination thereof of 30 to 99% compared to an untreated control. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The oligonucleotide and the pharmaceutical composition are used in a method of preventing and/or treating a viral disease.

Abstract: An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8, or 9; histidine having a concentration of 1 mM-100 mM; and an antioxidant and optionally a non-ionic tonicity agent. The pH value is around 5-9. The antioxidant is nicotinamide, which is at a concentration of 50 mM-1000 mM. The non-ionic tonicity agent is sorbitol, which is at a concentration of 0 mM-500 mM. A concentration of the PDSP is 0.01%-1% w/v.

Abstract: A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical composition further contains an antigen as a vaccine, wherein the TREML1 ECD or stalk polypeptide functions as an adjuvant or immune booster.

Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Abstract: A hepatitis B virus (HBV) vaccine includes an HBV core antigen (HBcAg) and/or HBV surface antigen (HBsAg) formulated in nanocomplexes. The nanocomplexes contain chitosan and ?-PGA. These nanocomplexes containing HBc/sAg, chitosan, and ?-PGA can induce more balanced T helper cells (Th1 and Th2) polarization than can a conventional vaccine with an alum adjuvant. HBc/s-NC of the invention can elicit high levels of antibodies against HBsAg, a rapid elimination of HBsAg, and a slow decrease of HBeAg, indicating a phenomenon of HBsAg seroconversion. Thus, HBc/s-NC can overcome immune tolerance caused by chronic HBV infection to re-establish host immunity leading a functional cure.

Abstract: A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs); suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood; and accelerated clearance of HBV from liver.

Abstract: A method for treating a tendon injury includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

Abstract: A method for treating and/or preventing osteoarthritis includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

Abstract: A pharmaceutical composition or method for promoting meibomian gland regeneration or for treating/preventing dry eye syndrome includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF).

Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Abstract: Various embodiments of the present invention generally relate to operating an electronic gaming machine to generate a wager-based game. A game control unit and a secure enclosure are provided. The secure enclosure is divided into two compartments. A game control unit including a game controller and two heat dissipation units is disposed within the first compartment. In a second compartment, which is fluidly coupled to the first compartment, fans are provided. The fans drive air from outside the secure enclosure through the heat dissipation units in the first compartment to cool electrical components associated with the game controller which are mounted on an outside of the heat dissipation units. The two heat dissipation units can each include fins and heat pipes. The ends of the fins of the two heat dissipation units can be substantially touching one another to provide a compact form factor.

Abstract: Various embodiments of the present invention generally relate to operating an electronic gaming machine to generate a wager-based game. A game control unit including a secure enclosure are provided. The secure enclosure is divided into two compartments. The first compartment securely contains the game control unit, which includes a game controller used to generate the wager-based game and heat dissipation units. The second compartment includes two fans and is accessed by an easily removable magnetically attached cover. The fans and heat dissipation units provide cooling for electrical components associated with the game controller. The fans can be maintained and replaced without compromising the security of the game controller. This feature reduces costs associated with maintaining the electronic gaming machine.

Abstract: Various embodiments of the present invention generally relate to operating an electronic gaming machine to generate a wager-based game. A game control unit and a secure enclosure are provided. The secure enclosure is divided into two compartments. A game control unit including a game controller and two heat dissipation units is disposed within the first compartment. In a second compartment, which is fluidly coupled to the first compartment, fans are provided. The fans drive air from outside the secure enclosure through the heat dissipation units in the first compartment to cool electrical components associated with the game controller which are mounted on an outside of the heat dissipation units. The two heat dissipation units can each include fins and heat pipes. The ends of the fins of the two heat dissipation units can be substantially touching one another to provide a compact form factor.

Abstract: Various embodiments of the present invention generally relate to operating an electronic gaming machine to generate a wager-based game. A game control unit including a secure enclosure are provided. The secure enclosure is divided into two compartments. The first compartment securely contains the game control unit, which includes a game controller used to generate the wager-based game and heat dissipation units. The second compartment includes two fans and is accessed by an easily removable magnetically attached cover. The fans and heat dissipation units provide cooling for electrical components associated with the game controller. The fans can be maintained and replaced without compromising the security of the game controller. This feature reduces costs associated with maintaining the electronic gaming machine.

Abstract: A sensitive lighting fixture, adapted for incorporating with the construction junction box built on wall, ceiling or floor to form a utility lighting device, includes a base seat including a front plate and a recessed case rearwardly extended from the front plate, a light source disposed in the light source socket, a light shade detachably attached to the front plate of base seat and sized to cover the light source opening, a control sensor provided on the front plate of the base seat and exposed to outside, and a control device for electrically connecting the light source with the electric wires extended inside the construction junction box and electrically connecting the control sensor and the light source in such a manner that the control sensor turns the light source off when the visible light detector detects ambient light and on when the control sensor does not detect ambient light.

Abstract: A sensitive lighting fixture is specifically designed to incorporate with the construction junction box built on wall, ceiling or floor to form a utility lighting device, wherein the sensitive lighting fixture includes a base seat including a front plate and a recessed case rearwardly extended from the front plate, a light source disposed in the light source socket, a light shade detachably attached to the front plate of base seat and sized to cover the light source opening, a control sensor provided on the front plate of the base seat and exposed to outside, and a control device for electrically connecting the light source with the electric wires extended inside the construction junction box and electrically connecting the control sensor and the light source in such a manner that the control sensor turns the light source off when the visible light detector detects ambient light and on when the control sensor does not detect ambient light.